Your browser doesn't support javascript.
loading
Non-rhabdomyosarcoma soft-tissue sarcoma.
Milgrom, Sarah A; Million, Lynn; Mandeville, Henry; Safwat, Akmal; Ermoian, Ralph P; Terezakis, Stephanie.
Afiliação
  • Milgrom SA; Department of Radiation Oncology, University of Colorado, Denver, Colorado.
  • Million L; Department of Radiation Oncology, Stanford University, Stanford, California.
  • Mandeville H; Department of Radiation Oncology, Royal Marsden Hospital, London, UK.
  • Safwat A; Department of Radiation Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Ermoian RP; Department of Radiation Oncology, University of Washington, Seattle, Washington.
  • Terezakis S; Department of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota.
Pediatr Blood Cancer ; 68 Suppl 2: e28279, 2021 05.
Article em En | MEDLINE | ID: mdl-33818885
ABSTRACT
Non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS) comprise 4% of childhood cancers and consist of numerous histologic subtypes. Prognostic factors associated with poor outcome include high histologic grade, large tumor size, presence of metastases, and unresectability. Complete surgical resection is critical for the best oncologic outcomes and is prioritized in treatment algorithms. The use of radiation therapy (RT) and chemotherapy is based upon factors such as resectability, histologic grade, tumor size, and stage. North American and European trials are defining a risk-based approach to NRSTS to limit treatment-related toxicity and to maximize therapeutic efficacy. In this paper, we summarize the current roles of surgery, RT, and chemotherapy in NRSTS and describe ongoing research that is advancing the care of NRSTS patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma Idioma: En Ano de publicação: 2021 Tipo de documento: Article